OnabotulinumtoxinA vs Sacral Neuromodulation for Urgency Incontinence-Reply
- PMID: 28170477
- PMCID: PMC5534324
- DOI: 10.1001/jama.2016.19566
OnabotulinumtoxinA vs Sacral Neuromodulation for Urgency Incontinence-Reply
Comment on
-
OnabotulinumtoxinA vs Sacral Neuromodulation for Urgency Incontinence.JAMA. 2017 Feb 7;317(5):534-535. doi: 10.1001/jama.2016.19560. JAMA. 2017. PMID: 28170473 No abstract available.
-
OnabotulinumtoxinA vs Sacral Neuromodulation for Urgency Incontinence.JAMA. 2017 Feb 7;317(5):535. doi: 10.1001/jama.2016.19563. JAMA. 2017. PMID: 28170474 No abstract available.
References
-
- Nitti VW, Ginsberg D, Sievert KD, Sussman D, Radomski S. Durable Efficacy and Safety of Long Term OnabotulinumtoxinA treatment in Patients with OAB Syndrome: Final Results of a 3.5 yr study. J Urol. 2016;196:791–800. - PubMed
-
- Dmochowski R, Chaple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized dose ranging trial. J Urol. 2010;184(6):2416–2422. - PubMed
-
- Jadad AR, Enkin MW. Bias in Randomized Controlled Trials, in Randomized 60 Controlled Trials: Questions, Answers, and Musings. 2. Vol. 61. Blackwell Publishing Ltd; Oxford, UK: 2007. - DOI
-
- Sackett DL. Choosing the best research design for each question: It’s time to stop squabbling for the “best” method. British Medical Journal. 1997;315:1626.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
